Characterized by high incidence and long treatment durations, the breast cancer therapy market represents substantial commercial opportunity for drug developers. CDK4\/6 inhibitors (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio\/Verzenios) are creating new dynamics in the treatment of metastatic HR-positive\/HER2-negative disease. Meanwhile, novel HER2-targeted agents, label expansions, and biosimilar entries\u2014all of which will lead to changes in treatment guidelines\u2014will have an impact on sales of current drugs for HER2-positive breast cancer. Furthermore, the approval of PARP inhibitors (AstraZeneca \/ Merck & Co.\u2019s Lynparza and Pfizer\u2019s Talzenna), immune checkpoint inhibitors (Roche \/ Genentech \/ Chugai\u2019s Tecentriq and Merck & Co.\u2019s Keytruda), PI3K inhibitors (Novartis\u2019s Piqray), HER2-targeted agents (Daiichi Sankyo \/ AstraZeneca\u2019s Enhertu, Seagen \/ Pfizer\u2019s Tukysa, and MacroGenics\u2019 Margenza), and TROP2-targeted agents (Gilead\u2019s Trodelvy), as well as the anticipated entry of other agents from these drug classes, will diversify treatment options, especially for triple-negative breast cancer.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n PRODUCT DESCRIPTION<\/strong><\/p>\n Disease Landscape & Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n SOLUTION ENHANCEMENT<\/strong><\/p>\n Disease Landscape & Forecast<\/em> will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n CONTENT HIGHLIGHTS<\/strong><\/p>\n\n
\n